Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Doxorubicin and imatinib co-loaded pegylated nanostructured carriers to effectively overcome doxorubicin resistance in metastatic tumors

  • In: Poster presentation
  • At: Seoul (South Korea) (2017)
  • Type: Poster
  • Poster code: POS-FDP-036
  • By: YONG, Chul Soon (Yeungnam University, Gyeongsan-Si, Korea, Republic Of)
  • Co-author(s): Jae Hee Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Biki Gupta: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Shiva Pathak: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Raj Kumar Thapa: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Jee-Heon Jeong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Dong Shik Kim: Hanyang University, Ansan-si, Korea, Republic Of
    Han-Gon Choi: Hanyang University, Ansan-si, Korea, Republic Of
    Chul Soon Yong: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
    Jong Oh Kim: Yeungnam University, Gyeongsan-Si, Korea, Republic Of
  • Abstract:

    Background

    Resistance to chemotherapeutic agents is viewed as a major impediment to successful treatment of metastatic cancers. Doxorubicin(DOX) is often associated with recurrence or metastasis of cancers, primarily as a result of development of multidrug resistance(MDR).

    Purpose

    The purpose was to prepare PEGylated-nanostructured platforms for..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses